Reach Us +44-1904-929220
Biomarker Discovery Using Proteins Identified Across Disease | 8872

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Biomarker discovery using proteins identified across disease

4th International Conference on Biomarkers & Clinical Research

Leticia Cano

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.017

Biomarker discovery is a difficult series of experiments due to the number of different molecules in clinical samples, the wide dynamic range of these molecules, their fluctuations and modifications. Often, it is difficult to determine which molecules should be selected as biomarker candidates for a particular purpose. Biomarkers can be used as indicators of disease, disease progression, and response to therapy or complications. Often disease is studied in comparison to healthy controls. However, we find that the comparison of biomarkers across different disease yields a different set of candidates than if the disease were studied in isolation. In this talk, we will present our discovery strategy and discuss the development of a biomarker database to aid in biomarker selection
Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her Ph.D. dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis Systemic Lupus Erythematosis. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery
Relevant Topics